Fenretinide: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 351 patientsc19early.org

Fenretinide for COVID-19

Serious outcome risk
Fenretinide
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−44%
Mortality (1)−44%
RCTs (1)−44%
Late (1)−44%
00.511.5+
← Fenretinide
reduces riskIncreased
risk →
c19early.org
October 2026

Fenretinide COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Houle (DB RCT)−44%1.44 · 0.71–2.93death17/17412/177RESOLUTION
Late treatment−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.32
All studies−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3200.511.52+
Rotate screen for more detailsIncrease width for more details
← Fenretinide
reduces riskFenretinide
increases risk →
c19early.org
October 2026

Fenretinide COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Houle (DB RCT)−44%1.44 · 0.71–2.9317/17412/177RESOLUTION
Late treatment−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.32
All studies−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3200.511.52+
Rotate screen for more detailsIncrease width for more details
← Fenretinide
reduces riskFenretinide
increases risk →
c19early.org
October 2026

Fenretinide COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Houle (DB RCT)−44%1.44 · 0.71–2.93death17/17412/177RESOLUTION
Late treatment−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.32
All studies−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3200.511.52+
Rotate screen for more detailsIncrease width for more details
← Fenretinide
reduces riskFenretinide
increases risk →
c19early.org
October 2026

Fenretinide COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Houle (DB RCT)−44%1.44 · 0.71–2.93death17/17412/177RESOLUTION
Late treatment−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.32
All studies−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3200.511.52+
Rotate screen for more detailsIncrease width for more details
← Fenretinide
reduces riskFenretinide
increases risk →
c19early.org
October 2026

Fenretinide COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Houle (DB RCT)−44%1.44 · 0.71–2.9317/17412/177RESOLUTION
Late treatment−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.32
All studies−44%1.44 · 0.71–2.9317/17412/17744% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3200.511.52+
Rotate screen for more detailsIncrease width for more details
← Fenretinide
reduces riskFenretinide
increases risk →